Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Intravenous Immunoglobulin (IVIG) in the Treatment of Small Fiber Neuropathy Due to TS-HDS, FGFR-3, or Plexin D1 Antibodies: a Double Blinded Placebo-controlled Phase II Trial

NCT04153422 is registered in ClinicalTrials.gov with Endeavor Health as lead sponsor.

NCT NCT04153422
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04153422 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Intravenous Immunoglobulin (IVIG) in the Treatment of Small Fiber Neuropathy Due to TS-HDS, FGFR-3, or Plexin D1 Antibodies: a Double Blinded Placebo-controlled Phase II Trial
Lead sponsor
Endeavor Health
Phase
Phase 2
Overall status
Recruiting
Start date
December 15, 2023
Completion date
February 28, 2028
Enrollment
20 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

autoimmune small fiber neuropathy, immune-mediated neuropathy, inflammatory polyneuropathy, small fiber neuropathy